Search

Your search keyword '"Lingler, Jacqui"' showing total 12 results
Start Over Author "Lingler, Jacqui"
12 results on '"Lingler, Jacqui"'

4. Double-Blind Maintenance Safety and Effectiveness Findings From the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) Study

Author

Findling, Robert L., Johnson, Jacqueline L., McClellan, Jon, Frazier, Jean A., Vitiello, Benedetto, Hamer, Robert M., Lieberman, Jeffrey A., Ritz, Louise, McNamara, Nora K., Lingler, Jacqui, Hlastala, Stefanie, Pierson, Leslie, Puglia, Madeline, Maloney, Ann E., Kaufman, Emily Michael, Noyes, Nancy, and Sikich, Linmarie

Published
2010
Full Text
View/download PDF

5. The short-term safety and efficacy of fluoxetine in depressed adolescents with alcohol and cannabis use disorders: a pilot randomized placebo-controlled trial

Author

Lingler Jacqui, Faber Jon E, Stansbrey Robert J, McNamara Nora K, Pagano Maria E, Findling Robert L, Demeter Christine A, Bedoya Denise, and Reed Michael D

Subjects
Pediatrics, RJ1-570, Psychiatry, RC435-571
Abstract

Abstract Background The objective of this study was to examine whether fluoxetine was superior to placebo in the acute amelioration of depressive symptomatology in adolescents with depressive illness and a comorbid substance use disorder. Methods Eligible subjects ages 12–17 years with either a current major depressive disorder (MDD) or a depressive disorder that were also suffering from a comorbid substance-related disorder were randomized to receive either fluoxetine or placebo in this single site, 8-week double-blind, placebo-controlled study. The primary outcome analysis was a random effects mixed model for repeated measurements of Children's Depression Rating Scale-Revised (CDRS-R) scores compared between treatment groups across time. Results An interim analysis was performed after 34 patients were randomized. Based on the results of a futility analysis, study enrollment was halted. Twenty-nine males and 5 females were randomized to receive fluoxetine (n = 18) or placebo (n = 16). Their mean age was 16.5 (1.1) years. Overall, patients who received fluoxetine and placebo had a reduction in CDRS-R scores. However, there was no significant difference in mean change in CDRS-R total score in those subjects treated with fluoxetine and those who received placebo (treatment difference = 0.19, S.E. = 0.58, F = 0.14, p = .74). Furthermore, there was not a significant difference in rates of positive urine drug toxicology results between treatment groups at any post-randomization visit (F = 0.22, df = 1, p = 0.65). The main limitation of this study is its modest sample size and resulting low statistical power. Other significant limitations to this study include, but are not limited to, the brevity of the trial, high placebo response rate, limited dose range of fluoxetine, and the inclusion of youth who met criteria for depressive disorders other than MDD. Conclusion Fluoxetine was not superior to placebo in alleviating depressive symptoms or in decreasing rates of positive drug screens in the acute treatment of adolescents with depression and a concomitant substance use disorder.

Published
2009
Full Text
View/download PDF

7. Lithium in the Acute Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled Study

Author

Findling, Robert L., primary, Robb, Adelaide, additional, McNamara, Nora K., additional, Pavuluri, Mani N., additional, Kafantaris, Vivian, additional, Scheffer, Russell, additional, Frazier, Jean A., additional, Rynn, Moira, additional, DelBello, Melissa, additional, Kowatch, Robert A., additional, Rowles, Brieana M., additional, Lingler, Jacqui, additional, Martz, Karen, additional, Anand, Ravinder, additional, Clemons, Traci E., additional, and Taylor-Zapata, Perdita, additional

Published
2015
Full Text
View/download PDF

8. An Open-Label Study of Aripiprazole in Children with a Bipolar Disorder

Author

Findling, Robert L., primary, McNamara, Nora K., additional, Youngstrom, Eric A., additional, Stansbrey, Robert J., additional, Frazier, Thomas W., additional, Lingler, Jacqui, additional, Otto, Benjamin D., additional, Demeter, Christine A., additional, Rowles, Brieana M., additional, and Calabrese, Joseph R., additional

Published
2011
Full Text
View/download PDF

9. Dosing Strategies for Lithium Monotherapy in Children and Adolescents with Bipolar I Disorder

Author

Findling, Robert L., primary, Kafantaris, Vivian, additional, Pavuluri, Mani, additional, McNamara, Nora K., additional, McClellan, Jon, additional, Frazier, Jean A., additional, Sikich, Linmarie, additional, Kowatch, Robert, additional, Lingler, Jacqui, additional, Faber, Jon, additional, Rowles, Brieana M., additional, Clemons, Traci E., additional, and Taylor-Zapata, Perdita, additional

Published
2011
Full Text
View/download PDF

10. First-Dose Pharmacokinetics of Lithium Carbonate in Children and Adolescents

Author

Findling, Robert L., primary, Landersdorfer, Cornelia B., additional, Kafantaris, Vivian, additional, Pavuluri, Mani, additional, McNamara, Nora K., additional, McClellan, Jon, additional, Frazier, Jean A., additional, Sikich, Linmarie, additional, Kowatch, Robert, additional, Lingler, Jacqui, additional, Faber, Jon, additional, Taylor-Zapata, Perdita, additional, and Jusko, William J., additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results